Advertisement
Significant disparities in care and outcomes exist for children with retinoblastoma

Significant Disparities in Care for Pediatric Retinoblastoma

0
Extraocular disease higher among Hispanic children, counties with low socioeconomic status
Magnetic resonance imaging is an accurate and safe tool for the detection of low levels of iron overload in patients with hereditary hemochromatosis

MRI Effectively Measures Hemochromatosis Iron Burden

0
MRI tested in detection of iron stores in heart, liver and spleen, and pancreas
A study of more than five million Swedish men and women suggests that greater height may mean greater risk of cancer. The findings were presented at the annual meeting of the European Society for Pediatric Endocrinology

Taller Individuals Appear More Likely to Develop Cancer

0
Mortality association remains unclear
A new treatment for melanoma that combines two cancer drugs has been approved by the U.S. Food and Drug Administration. The therapy for advanced melanoma includes the drugs Yervoy (ipilimumab) and Opdivo (nivolumab)

FDA Approves New Combo Therapy for Melanoma

0
Yervoy and Opdivo previously approved individually to treat melanoma
In order to minimize risk when practicing telemedicine

Providers Must Understand Legal Limits of Telemedicine

0
Providers should ensure they hold proper medical license and have medical liability coverage
Stage IV nonsmall-cell lung cancer patients in the United States often receive more radiation therapy than recommended

Palliative Radiotherapy Often Overused in Stage IV NSCLC

0
Not proven to further improve symptoms or quality of life; can have significant side effects
Keytruda (pembrolizumab) has been approved by the U.S. Food and Drug Administration to treat advanced cases of non-small-cell lung cancer with tumors that express the PD-L1 protein. Keytruda is approved for use with the PD-L1 IHC 22C3 pharmDx test

FDA Approves Keytruda for Advanced NSCLC

0
Approved for use with PD-L1 IHC 22C3 pharmDx test
For women with epithelial ovarian cancer

Adjuvant Hormone Tx Ups Survival in Epithelial Ovarian CA

0
Significant improvement in overall, relapse-free survival for women receiving five-years of AHT
An integrative model incorporating cancer care into primary care is recommended for addressing the increasing burden of cancer control

Integrative Model Is Advised for Cancer Control in Primary Care

0
The Lancet Oncology Commission recommends model for dealing with increasing burden of cancer care
A new study has identified significant differences between non-small-cell lung cancer patients who smoke and those who don't. The findings were presented Sunday at the annual meeting of the European Respiratory Society

Differences Found in Smokers, Nonsmokers Who Develop NSCLC

0
Nonsmokers more likely than smokers to be women and to have adenocarcinoma